GUANGZHOU, China, May 5 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME) (“China Medicine” or “the Company”), a leading distributor and developer of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (“TCM”), nutritional and dietary-supplements, medical devices, and medical formulations in the People’s Republic of China (“PRC”), announced today that the Company’s management will present at the upcoming China Rising Conference hosted by CCG Investor Relations in New York, NY on May 18, 2009.
The date, time and location of China Medicine’s presentation at the China Rising Conference are as follows:
Date: Monday, May 18, 2009
Time: 1:30 p.m. to 2:00 p.m. Eastern Time
Presenter: Mr. Senshan Yang, Chief Executive Officer
Ms. Minhua Liu, Executive Vice President
Ms. Gavin Chen, CFO Assistant
Venue: The Yale Club
50 Vanderbilt Avenue
New York, NY 10017
Webcast: http://www.chinarisingconference.com/webcast.html
A replay of the webcast will be available for up to one year following the presentation using the same link.
The China Rising Investment Conference hosted by CCG Investor Relations will provide over 250 fund managers and investors access to senior management of a wide range of Chinese growth companies in sectors including consumer staples, agriculture, pharmaceuticals, infrastructure, information technology, advanced materials, capital goods, and alternative energy. The conference will include over 30 US-listed Chinese companies and a number of private companies.
Interested parties and investors may find more information for the conference by visiting the website at http://www.chinarisingconference.com.
About China Medicine Corporation
China Medicine Corporation is a developer and leading distributor of prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. China Medicine also has its research and development force for certain products it manufactures through OEM arrangement makes the distribution. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company’s website at http://www.chinamedicinecorp.com
Cautionary Statement
This press release contains forward-looking statements concerning the Company’s business and products. The Company’s actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
Company Contact: Investor Relations Contact:
Ms. Huizhen Yu Mr. Crocker Coulson, President
Chief Financial Officer CCG Investor Relations
China Medicine Corp Tel: +1-646-213-1915 (NY Office)
Tel: +86-20-8739-1718 E-mail: crocker.coulson@ccgir.com
E-mail: konzern08@163.com Website: www.ccgirasia.com
